Probable REM Sleep Behavior Disorder Is a Risk Factor for Symptom Progression in Parkinson Disease

Ashley Barasa¹, Jijia Wang² and Richard B. Dewey Jr.¹*

¹ Department of Neurology, UT Southwestern Medical Center, Dallas, TX, United States, ² Department of Applied Clinical Research, Southwestern School of Health Professions, UT Southwestern Medical Center, Dallas, TX, United States

Background: The literature is conflicting on whether rapid eye movement sleep behavior disorder (RBD) is associated with more rapid progression of Parkinson disease (PD).

Objective: We aimed to determine (1) how stable probable RBD (pRBD) is over time and (2) whether it predicts faster PD progression.

Methods: We evaluated participants in the Parkinson’s Disease Biomarker Project (PDBP) who were prospectively assessed every 6–12 months with a series of motor, non-motor, disability, and health status scales. For aim 1, we calculated the incidence and disappearance rates of pRBD and compared stability of pRBD in PD with control subjects. For aim 2, we developed multiple regression models to determine if pRBD at baseline influenced the rate of change or average value at 48 months of 10 outcome variables.

Results: We found that pRBD was a less stable diagnosis for PD than controls. In pRBD+ subjects, the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III score progressed 2.78 points per year faster (p < 0.01), MDS-UPDRS total score progressed 3.98 points per year faster (p < 0.01), a global composite outcome (GCO) worsened by 0.09 points per year faster (p = 0.02), and Parkinson’s Disease Questionnaire (PDQ-39) mobility score progressed 2.57 percentage points per year faster (p < 0.01). The average scores at 48 months were 8.89 (p = 0.02) and 14.3 (p = 0.01) points higher for pRBD+ in MDS-UPDRS part III and total scores, respectively.

Conclusions: Our study confirms that pRBD detected at the start of a study portends more rapid progression of PD. Knowing this could be useful for enriching clinical trials with fast progressors to accelerate discovery of a disease modifying agent.

Keywords: Parkinson disease, REM sleep behavior disorder, progression, severity, prediction
INTRODUCTION

The degeneration of brain dopamine pathways is the pathophysiologic hallmark of idiopathic Parkinson disease (PD). Loss of brain dopamine is the primary basis of the cardinal motor signs which are substantially reversed by dopaminergic drug therapy. While dopamine deficiency may play a role in certain non-motor features such as depression and anxiety (1), it is now clear that PD is a multisystem degenerative disease. Rapid eye movement (REM) sleep behavior disorder (RBD) is one such non-dopaminergic feature seen commonly in PD which is characterized by dream enactment behavior. Affected patients kick, thrash, punch, and vocalize during REM sleep and may injure themselves or their bed partners (2). The pathophysiology of RBD in humans is not completely understood, but it is suspected that an inhibitory projection from the pontine sublaterodorsal nucleus to the spinal cord degenerates, thus removing the normal paralysis of skeletal muscle during REM sleep (3). The prevalence of RBD in the general population is about 1% (4) as compared with that in PD of 42.3% (5). While several studies have emphasized that RBD is a prodromal feature of the alpha synucleinopathies (6–8), in another study, 55% of PD patients with RBD developed it either at the same time PD was diagnosed or after the diagnosis was made (9).

Because the presence of RBD in PD is associated with more widespread alpha synuclein deposition (10), a number of studies have addressed the question of whether RBD is associated with a more malignant form of PD. A recent review suggested that RBD portends a poor prognosis, yet the findings of several longitudinal studies were conflicting (11). While two studies were concordant in demonstrating an increased risk of dementia when RBD was present (RBD+) (12, 13), two studies suggested that RBD is a risk factor for hallucinations (13, 14), while another found no association (15). With respect to progression of motor features, one study found an increased risk in RBD+ as compared to RBD− subjects (16), another found no difference in motor progression between the groups (15). A significant limitation of these studies was the inclusion of relatively small numbers of subjects followed for relatively short periods of time.

Recently, this same question was addressed using the longitudinal Parkinson’s Progression Marker Initiative (PPMI) database of 421 drug-naïve patients with PD and 196 controls who were followed for 5 years. The authors defined motor progression as an increase of one point on the Hoehn and Yahr scale (H&Y) measured in the clinical “off” state and cognitive progression as a self-report of cognitive impairment with a Montreal Cognitive Assessment score (MoCA) of <26. They found using multivariate Cox hazard survival analysis that RBD+ was a predictor of motor progression with a hazard ratio (HR) of 1.49 and of cognitive progression with a HR of 2.0 (17).

Because a clear consensus has not yet emerged on the relationship between RBD and disease progression, we undertook evaluating this question using the Parkinson’s Disease Biomarker Project (PDBP) database which consists of 416 PD subjects and 156 controls with longitudinal assessments (18, 19). All but 31 PD subjects were treated with dopaminergic drugs at study entry. The duration of follow-up was variable based on when they were enrolled during the 5 year project. The aims of this study were (1) to determine if a diagnosis of probable RBD (pRBD+) is stable during longitudinal follow-up and (2) to identify whether pRBD+ at baseline is a risk factor for motor, non-motor, or cognitive progression.

METHODS

Standard Protocol Approvals, Registrations, and Patient Consents

The study protocol was reviewed and approved by the Institutional Review Board of the University of Texas Southwestern Medical Center and by the other institutions that collected data from subjects. Written informed consent was obtained from all participants. The study was registered on clinicaltrials.gov with registration number NCT01767818. The study is reported in accordance with STROBE reporting criteria for cohort studies.

Subjects

PD subjects had a diagnosis of idiopathic PD according to UK Brain Bank Criteria (20), were male or female age 30 years old or older at the time of diagnosis, if untreated with dopaminergic agents had confirmation of dopamine transporter deficit by I-123 Ioflupane SPECT (DatScan), and if treated with dopaminergic agents had clinical evidence of a favorable response to treatment. Subjects were excluded if they had confirmed or suspected atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases. Control subjects were drawn from a convenience sample of roughly aged-matched persons without degenerative neurologic diseases in the same geographical area as the PD subjects. Many of the controls were spouses or partners of PD subjects.

RBD Diagnosis

The American Academy of Sleep Medicine has established criteria for RBD that require the presence of REM sleep without atonia on polysomnography (PSG) (21). Because repetitive PSG is impractical for a large longitudinally followed cohort study, survey instruments have been developed to identify pRBD. We used the Mayo Sleep Questionnaire (MSQ) to identify RBD when a “yes” was given to question 1 and a “no” to question 5. Question 1 identifies those with dream enactment behavior, and question 5 excludes those with symptoms suggestive of sleep apnea. The use of these two questions is associated with a sensitivity and specificity for detecting RBD of 98% and greater than 74%, respectively (22). In this report we refer to our subjects as having pRBD due to the lack of PSG confirmation. However, it should be noted that the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines RBD without the need for PSG in patients who have the appropriate symptoms in the context of a synucleinopathy diagnosis (23). The MSQ was obtained annually from baseline until the last visit.

The incidence rate for onset of pRBD was calculated as the number of new pRBD+ cases divided by the time elapsed in years divided by the total number of pRBD− cases at baseline. The rate of disappearance of pRBD was calculated as the number
of pRBD+ cases at baseline who converted to pRBD− at the end of the study divided by the time elapsed in years divided by the number of pRBD+ cases at baseline as previously described (15).

Clinical Assessments
Clinical assessments performed every 6 months included the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (24) and the levodopa equivalent daily dose (LEDD) calculated from detailed drug administration records available at each visit. The LEDD was calculated according to Tomlinson and others (25) as modified by incorporating the daily dose of carbidopa and levodopa extended-release capsules (Rytary) × 0.7 and carbidopa/levodopa enteral suspension (Duopa) × 0.97. We also recorded the number of subjects from each group taking on a scheduled basis at baseline dopamine agonists (pramipexole, ropinirole, and rotigotine), sedating antidepressants (trazodone and doxepin), quetiapine, benzodiazepines (clonazepam, diazepam, alprazolam, lorazepam, and elprazolam), prescription sleep aids (zolpidem and eszopiclone), and melatonin. Every 12 months the following scales were obtained: Hamilton Anxiety Scale (HAM-A) (26), Hamilton Depression Scale (HAM-D) (27), Montreal Cognitive Assessment (MoCA) (28), Parkinson’s Disease Questionnaire (PDQ-39) (29), Epworth Sleepiness Scale (ESS) (30), Modified Schwab and England Activities of Daily Living Scale (S&E) (31), and University of Pennsylvania Smell Identification Test (UPSIT) (32). We also calculated a global composite outcome (GCO) which combines parts...

| Variable       | Control | pRBD− | pRBD+ | P-value for RBD− vs. RBD+ | P-value for three groups |
|----------------|---------|-------|-------|---------------------------|-------------------------|
| n              | 137     | 229   | 108   |                           |                         |
| Age*           | 65.16 ± 15.0 | 63.97 ± 13.0 | 66.18 ± 9.0 | 0.037                     | 0.124                   |
| Education years | 15.70 ± 5.0  | 15.57 ± 5.0  | 15.79 ± 5.0  | 0.477                     | 0.758                   |
| Sex (M)        | 45.99% | 60.09% | 57.41% | 0.641                     | 0.028                   |
| Hispanic or Latino | 1.60% | 4.21% | 4.95% | 0.765                     | 0.337                   |
| Years with PD* | 4.24 ± 5.0  | 4.24 ± 5.0  | 6.44 ± 7.0  | <0.0001                   |                         |
| MDS-UPDRS Part I | 3.61 ± 4.0 | 7.96 ± 7.0  | 9.27 ± 6.5  | 0.057                     | <0.0001                 |
| MDS-UPDRS Part II | 0.47 ± 0.0 | 8.86 ± 9.0  | 10.15 ± 11.0 | 0.159                    | <0.0001                 |
| MDS-UPDRS Part III | 3.80 ± 4.0 | 21.14 ± 14.0 | 22.06 ± 15.5 | 0.581                    | <0.0001                 |
| MDS-UPDRS Part IV* | 0.01 ± 0.0 | 1.94 ± 3.0  | 2.99 ± 6.0  | 0.009                     | <0.0001                 |
| MDS-UPDRS Total | 7.90 ± 7.0 | 39.90 ± 28.0 | 44.47 ± 30.5 | 0.128                    | <0.0001                 |
| MoCA           | 26.23 ± 4.0 | 25.79 ± 4.0 | 25.69 ± 5.0 | 0.832                     | 0.379                   |
| LEDD*          | 572.97 ± 466.0 | 704.73 ± 515.0 | 704.73 ± 515.0 | 0.012                    |                         |
| Schwab and England | 0.99 ± 0.0 | 0.88 ± 0.1  | 0.87 ± 0.1  | 0.513                     | <0.0001                 |
| PDQ-39 Mobility | 1.17 ± 0.0 | 13.23 ± 17.5 | 15.44 ± 17.5 | 0.334                    | <0.0001                 |
| PDQ-39 ADL      | 0.94 ± 0.0 | 16.04 ± 20.8 | 17.45 ± 20.8 | 0.488                    | <0.0001                 |
| PDQ-39 Emotional | 4.93 ± 8.3  | 13.20 ± 20.8 | 14.25 ± 16.6 | 0.545                    | <0.0001                 |
| PDQ-39 Stigma   | 0.36 ± 0.0 | 14.59 ± 25.0 | 12.85 ± 18.8 | 0.41                     | <0.0001                 |
| PDQ-39 Social Support | 2.43 ± 0.0 | 5.84 ± 8.3  | 6.46 ± 8.3  | 0.688                     | 0.011                   |
| PDQ-39 Cog. Impair* | 5.11 ± 6.2  | 15.80 ± 18.8 | 22.19 ± 25.0 | 0.001                    | <0.0001                 |
| PDQ-39 Communication | 1.89 ± 0.0 | 12.92 ± 16.7 | 15.11 ± 25.0 | 0.301                    | <0.0001                 |
| PDQ-39 bodily discomfort* | 11.92 ± 16.7 | 21.44 ± 33.3 | 26.87 ± 25.0 | 0.027                    | <0.0001                 |
| GCO             | 0.60 ± 0.2 | 0.19 ± 0.7  | 0.32 ± 0.7  | 0.164                     | <0.0001                 |
| HAM-A*          | 3.88 ± 4.0 | 6.17 ± 6.0  | 7.55 ± 6.0  | 0.03                     | <0.0001                 |
| HAM-D           | 2.66 ± 4.0 | 4.78 ± 5.0  | 5.24 ± 5.0  | 0.376                     | <0.0001                 |
| Epworth sleepiness* | 5.09 ± 4.0 | 7.24 ± 6.0  | 8.32 ± 6.0  | 0.047                     | <0.0001                 |
| UPSIT*          | 32.60 ± 6.0 | 20.38 ± 13.0 | 18.28 ± 8.0  | 0.02                     | <0.0001                 |
| Dopamine agonists* | 51.53% | 53.70% | 53.70% | <0.0001                 |                         |
| Sedating antidepressants | 3.06% | 4.63% | 4.63% | 0.564                     |                         |
| Quetiapine      | 2.62%  | 4.63%  | 4.63%  | 0.763                     |                         |
| Benzodiazepines | 6.55%  | 14.81% | 14.81% | 0.858                     |                         |
| Melatonin*      | 3.06%  | 0%     | 0%     | 0.016                     |                         |
| Sleep aids      | 2.18%  | 0.93%  | 0.93%  | 0.219                     |                         |

*pIndicates statistically significant pRBD+ vs. pRBD− (p < 0.05).

PD, Parkinson disease; MoCA, Montreal Cognitive Assessment; PDQ-39, Parkinson’s Disease Questionnaire; GCO, Global Composite Outcome; HAM-A, Hamilton Anxiety Scale; HAM-D, Hamilton Depression Scale; UPSIT, University of Pennsylvania Smell Identification Test.
I–III of the MDS-UPDRS, S&E, and MoCA according to the method of Fereshtehnejad and others (33). Each of the above scales, including subparts of each scale, were treated as outcome variables to determine if pRBD status at baseline was associated with symptom progression. Because a change of raters at one PDBP longitudinal site introduced an anomaly in the MDS-UPDRS part III data at visits following the 12 month assessment, we censored MDS-UPDRS part III and total scores from that site at visits from 18 months onward.

**Statistical Analysis**

The two-sample t-test and chi-square test were used for the comparison of clinical features at baseline. For aim 1, we compared the stability of pRBD over time using the Wilcoxon–Mann–Whitney test, where the stability index was calculated by dividing the total number of visits by the count of switch events +1. A switch event represents a subject switching diagnosis (pRBD– to pRBD+ and vice versa). A high stability index indicates a more stable diagnosis over time.

For aim 2, we used univariate linear regression to estimate the subject-specific rate of change per year in each outcome measure and from this predicted measurements at 48 months. We then conducted multiple regression models to identify if having pRBD at baseline affected the rate of change in the outcome variables while controlling for demographic (age, gender, education, and ethnicity) and clinical (LEDD at baseline and PD duration) variables.

All statistical analyses were carried out using SAS 9.4 (SAS Institute Inc, Cary, NC). Graphs were generated using Prism version 8 (GraphPad Software, LLC).

**RESULTS**

Three hundred thirty-seven PD subjects and 137 controls had baseline and at least one follow-up measure on the MSQ and were thus included in this analysis. As shown in Table 1, PD subjects who were pRBD+ at baseline were older, had a longer disease duration, and were taking higher doses of levodopa equivalents. Additionally, they were more likely to have motor fluctuations, olfactory dysfunction, anxiety, daytime sleepiness, and to endorse subjective difficulty with cognitive function and bodily discomfort. Regarding medication use potentially relevant to RBD, there was a higher percentage of patients taking dopamine agonists in the pRBD+ group and a lower percentage taking melatonin. No significant difference was seen in the percentage taking sedating antidepressants, quetiapine, benzodiazepines, or prescription sleep aids comparing the two groups.

Of the pRBD– PD subjects at baseline, the incidence rate of conversion to pRBD+ was 8.7% as compared to that in controls of 1.2% (p < 0.001). By contrast, the disappearance rate in PD

| Outcome                  | Estimate | 95% CI for estimate | P-value | R-squared for goodness of fit |
|--------------------------|----------|---------------------|---------|------------------------------|
| MDS-UPDRS Part I         | 0.46798  | (−0.13, 1.06)       | 0.1227  | 0.035                        |
| MDS-UPDRS Part II        | 0.32196  | (−0.40, 1.05)       | 0.3827  | 0.032                        |
| MDS-UPDRS Part III*      | 2.77659  | (0.78, 4.77)        | 0.0065  | 0.038                        |
| MDS-UPDRS Part IV        | −0.1759  | (−0.59, 0.24)       | 0.4025  | 0.043                        |
| MDS-UPDRS Part total*    | 3.98442  | (1.26, 6.71)        | 0.0043  | 0.065                        |
| MoCA                     | 0.17412  | (−0.14, 0.49)       | 0.2756  | 0.042                        |
| LEDD                     | −10.721  | (−44.05, 22.60)     | 0.5272  | 0.110                        |
| Schwab and England       | −0.01    | (−0.02, 0.00)       | 0.1564  | 0.017                        |
| GCO*                     | 0.08874  | (0.01, 0.17)        | 0.0234  | 0.051                        |
| Epworth Sleepiness Scale | 0.14562  | (−0.28, 0.57)       | 0.5019  | 0.033                        |
| UPSIT                    | 0.37048  | (−0.26, 1.00)       | 0.248   | 0.045                        |
| HAM-A                    | −0.3563  | (−1.00, 0.29)       | 0.2784  | 0.043                        |
| HAM-D                    | −0.156   | (−0.60, 0.29)       | 0.492   | 0.074                        |
| PDQ-39 Mobility*         | 2.57433  | (0.69, 4.46)        | 0.0076  | 0.039                        |
| PDQ-39 ADL               | 1.12134  | (−0.49, 2.74)       | 0.1727  | 0.041                        |
| PDQ-39 Emotional         | 0.77624  | (−1.07, 2.62)       | 0.4092  | 0.023                        |
| PDQ-39 Stigma            | 0.49178  | (−1.60, 2.58)       | 0.6438  | 0.010                        |
| PDQ-39 Social Support    | 0.6179   | (−0.98, 2.22)       | 0.4471  | 0.050                        |
| PDQ-39 Cognitive Impairment | 1.17589       | (−0.77, 3.13)     | 0.2363  | 0.020                        |
| PDQ-39 Communication     | 1.68476  | (−0.21, 3.58)       | 0.0815  | 0.020                        |
| PDQ-39 bodily discomfort  | 2.29803  | (−0.01, 4.60)       | 0.0508  | 0.053                        |

*Indicates statistically significant (p < 0.05). PD, Parkinson disease; MoCA, Montreal Cognitive Assessment; PDQ-39, Parkinson’s Disease Questionnaire; GCO, Global Composite Outcome; HAM-A, Hamilton Anxiety Scale; HAM-D, Hamilton Depression Scale; UPSIT, University of Pennsylvania Smell Identification Test.
FIGURE 1 | Multivariate linear regression of (A) MDS-UPDRS total score, (B) global composite outcome, and (C) PDQ-39 mobility subscale over 48 months comparing pRBD+ and pRBD− PD subjects. Error bars represent standard error of the mean.

| Table 3 | Multiple linear regression analysis showing the difference in average measurement at month 48 for each outcome measure (estimate represents pRBD+ at baseline minus pRBD− subjects). |
|-----------------|-----------------|-----------------|
| Outcome                  | Estimate        | 95% CI for estimate | P-value | R-squared for goodness of fit |
| MDS-UPDRS Part I                           | 2.09154         | (−0.29, 4.48)     | 0.0854  | 0.040                        |
| MDS-UPDRS Part II                          | 1.39865         | (−1.67, 4.47)     | 0.3704  | 0.151                        |
| MDS-UPDRS Part III                          | 8.89219         | (1.14, 16.64)     | 0.0247  | 0.069                        |
| MDS-UPDRS Part IV                           | −0.3562         | (−1.82, 1.11)     | 0.6327  | 0.063                        |
| MDS-UPDRS Part total                        | 14.2595         | (3.14, 25.37)     | 0.0121  | 0.130                        |
| MoCA                                       | 1.13738         | (−0.20, 2.47)     | 0.0942  | 0.140                        |
| LEDD                                        | −7.2608         | (−136.87, 122.35) | 0.9123  | 0.233                        |
| Schwab and England                         | −0.0303         | (−0.09, 0.03)     | 0.2852  | 0.081                        |
| GCO                                         | 0.28528         | (−0.03, 0.60)     | 0.0775  | 0.167                        |
| Epworth Sleepiness Scale                    | 1.07744         | (−0.59, 2.75)     | 0.2051  | 0.073                        |
| UPSIT                                       | 0.60998         | (−1.95, 3.17)     | 0.6393  | 0.114                        |
| HAM-A                                       | −0.8171         | (−3.27, 1.64)     | 0.5131  | 0.019                        |
| HAM-D                                       | −0.6758         | (−2.39, 1.04)     | 0.4386  | 0.075                        |
| PDQ-39 Mobility*                            | 8.8832          | (0.86, 16.91)     | 0.0302  | 0.144                        |
| PDQ-39 ADL                                   | 0.03898         | (−3.96, 4.44)     | 0.4216  | 0.152                        |
| PDQ-39 Emotional                            | 3.26148         | (−3.37, 9.90)     | 0.3342  | 0.034                        |
| PDQ-39 Stigma                               | −0.4285         | (−7.89, 7.04)     | 0.9101  | 0.021                        |
| PDQ-39 Social Support                       | 2.16916         | (−3.37, 7.71)     | 0.4416  | 0.025                        |
| PDQ-39 Cog. Impairment*                     | 8.42905         | (1.33, 15.53)     | 0.0201  | 0.043                        |
| PDQ-39 Communication                        | 4.57143         | (−2.70, 11.84)    | 0.217   | 0.074                        |
| PDQ-39 Bodily Discomfort*                   | 10.2371         | (2.01, 18.47)     | 0.0149  | 0.118                        |

*Indicates statistically significant (p < 0.05).

PD, Parkinson disease; MoCA, Montreal Cognitive Assessment; PDQ-39, Parkinson’s Disease Questionnaire; GCO, Global Composite Outcome; HAM-A, Hamilton Anxiety Scale; HAM-D, Hamilton Depression Scale; UPSIT, University of Pennsylvania Smell Identification Test.

The difference between pRBD+ and pRBD− average scores at 48 months computed from subject-specific univariate linear regression are shown in Table 3. pRBD+ at baseline was associated with significantly higher average MDS-UPDRS part III and total scores and PDQ-39 mobility, cognitive impairment, and bodily discomfort scores at 48 months.

**DISCUSSION**

Our analysis of the PDBP dataset of prospectively assessed PD subjects produced two major findings. First, we confirmed previous reports that pRBD is not a stable condition in PD subjects was 12.7% as compared to 17.5% in controls (ns). The mean pRBD stability index was 2.62 for PD and 3.25 for controls (p < 0.001) indicating that pRBD is a significantly less stable diagnosis in PD subjects.

Table 2 and Figure 1 show the results of the multivariate linear regression analysis evaluating whether pRBD+ status at baseline is associated with symptom progression as measured by a series of outcome measures. These models were adjusted by age, sex, years of education, ethnicity, LEDD at baseline, and years with PD. The results were that MDS-UPDRS part III and total scores, GCO, and PDQ-39 mobility score progressed more rapidly in pRBD+ PD subjects as compared to those who were pRBD− at baseline.
when assessed longitudinally by survey instruments (15, 16, 34). In our subjects, about 9–13% reported onset or resolution of pRBD during follow-up. Interestingly, a recent 3-year study of PD patients with known RBD found that while subjective ratings of RBD symptoms increased, decreased, or remained stable, REM sleep without atonia as shown by PSG increased over time in all subjects (35). This suggests that patient or bed partner ratings of dream enactment behavior are not particularly reliable indicators of RBD when measured repeatedly and that once the pathology underlying RBD has developed, it progresses over time. We speculate that the fluctuating responses on the MSQ in subjects with pRBD are related to treatment effects, bed partner attentiveness to the problem, amnesia for these events by patients, and random variability of symptoms.

Second, we found that pRBD at baseline was a risk factor both for rate of worsening of several outcomes and of worse average scores at 48 months. This was true for both objective motor scores and several subscales of the PDQ-39 health status measure. Taken together, these data support the developing consensus that RBD is a marker of more extensive underlying neurodegeneration (36, 37).

Limitations of our study include missing values for MDS-UPDRS part III at one of three sites caused by a change in the clinical rater. This reduced the amount of available data for this outcome measure at later time points and highlights the importance of maintaining a consistent rater for motor scales in longitudinal investigations, even when, as in this case, all raters were certified in performing the MDS-UPDRS following the training program provided by the International Parkinson and Movement Disorder Society. Another limitation was the use of the MSQ for identification of RBD, which as noted earlier, is less reliable than PSG. Our use of this questionnaire potentially underestimated the number of subjects diagnosed with RBD because only those with clinically significant symptoms were identified. Fewer controls were recruited as compared to PD subjects because the priority for the PDBP project was earlier, is less reliable than PSG. Our use of this questionnaire potentially underestimated the number of subjects diagnosed with RBD because only those with clinically significant symptoms were identified. Fewer controls were recruited as compared to PD subjects because the priority for the PDBP project was to collect clinical and biospecimens on individuals with PD. Finally, the follow-up time varied among subjects with those entering the study in the first year of recruitment having longer follow-up than those recruited later during the project. This problem was managed by using univariate linear regression to model the subject-specific rate of progression of each outcome variable through 48 months. The strengths of our study are the longitudinal design, prospective data collection, the large number of subjects, and the availability of age-matched controls.

Our results add to the growing body of literature indicating that pRBD is linked to more rapid worsening of both motor and health status metrics when present in PD. This finding is important because clinically significant pRBD can be detected using simple patient/sleep partner survey instruments and the pRBD + status suggests that a patient is likely to be a fast progressor. This knowledge, in turn, will be useful not only for more accurate individual prognostication in the clinic but may help investigators select subjects who are destined to be fast progressors for inclusion in disease modifying research trials.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found at: https://pdbp.ninds.nih.gov/how-to-guide#request-access-to-the-dmr.

**ETHICS STATEMENT**

This study involving human participants was reviewed and approved by the Institutional Review Board of the University of Texas Southwestern Medical Center, and by the other institutions that collected data from subjects. The participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

AB: research project—organization and execution, statistical analysis—review and critique, and manuscript—writing of the first draft. JW: research project—execution, statistical analysis—design and execution, manuscript—review and critique. RD: research project—conception, organization, and execution, statistical analysis—review and critique, manuscript—review and critique. All authors contributed to the article and approved the submitted version.

**FUNDING**

RD was supported by NINDS U01-NS082148 and the Jean Walter Center for Research in Movement Disorders.

**ACKNOWLEDGMENTS**

Data and biospecimens used in preparation of this manuscript were obtained from the Parkinson’s Disease Biomarkers Program (PDBP) Consortium, supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Investigators include Roger Albin, Roy Alcalay, Alberto Ascherio, Thomas Beach, Sarah Berman, Bradley Boeve, F. DuBois Bowman, Shu Chen, Alice Chen-Plotkin, William Dauer, Ted Dawson, Paula Desplats, Richard Dewey, Ray Dorsey, Jori Fleisher, Kirk Frey, Douglas Galasko, James Galvin, Dwight German, Lawrence Honig, Xuemei Huang, David Irwin, Kejal Kantarci, Anumanta Kanthasamy, Daniel Kaufe, James Leverenz, Carol Lippa, Irene Litvan, Oscar Lopez, Jian Ma, Lara Mangravite, Karen Marder, Laurie Orzelius, Vladislav Petyuk, Judith Potashkin, Liana Rosenthal, Rachel Saunders-Pullman, Clemens Scherzer, Michael Schwarzschild, Tanya Simuni, Andrew Singleton, David Standaert, Debby Tsuang, David Vaillancourt, David Walt, Andrew West, Cyrus Zabetian, Jing Zhang, and Wenquan Zou. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript. We also thank Drs. Shilpa Chitnis, Pravin Khemani, and Neepa Patel for helping to recruit and follow participants and Ashley Gerald for her coordination of the study at UT Southwestern. Study funding: NINDS U01-NS082148.
REFERENCES

1. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology. (1995) 45:1757–60. doi: 10.1212/WNL.45.8.1757

2. Schenck CH, Bundlie SR, Ettiger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. (1986) 9:293–308. doi: 10.1093/sleep/9.2.293

3. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, et al. Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain. (2007) 130:2770–88. doi: 10.1093/brain/awn056

4. Haba-Rubio J, Frauscher B, Marques-Vidal P, Toriel J, Tobbback N, Andries JR, et al. Prevalence and determinants of rapid eye movement sleep movement behavior disorder in the general population. Sleep. (2018) 41:ssx197. doi: 10.1093/sleep/ssx197

5. Zhang X, Sun X, Wang J, Tang L, Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson’s disease: a meta and meta-regression analysis. Neurol Sci. (2017) 38:163–70. doi: 10.1007/s10072-016-2744-1

6. Galbiati A, Verga I, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. (2019) 43:37–46. doi: 10.1016/j.smrv.2018.09.008

7. Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, et al. Risk and predictors of dementia and parkinsonism in REM sleep behavior disorder: a multicentre study. Brain. (2019) 142:744–59. doi: 10.1093/brain/awz030

8. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. (2015) 14:744–7. doi: 10.1016/j.sleep.2012.10.009

9. De Cock VC, Vidalhelt M, Leu S, Texeira A, Apartis E, Elbaz A, et al. Restoration of normal motor control in Parkinson’s disease. Mov Disord. (2018) 33:1829–37. doi: 10.1002/mds.27381

10. Postuma RB, Adler CH, Dugger BN, Hentz JG, Shill HA, Driver-Dunckley E, et al. REM sleep behavior disorder and neurodegeneration in Parkinson’s disease. Mov Disord. (2015) 30:1413–7. doi: 10.1002/mds.26347

11. Kim Y, Kim YE, Park EO, Shin CW, Kim HJ, Jeon B. REM sleep behavior disorder portends poor prognosis in Parkinson’s disease: a systematic review. J Clin Neurosci. (2018) 47:6–13. doi: 10.1016/j.jocn.2017.09.019

12. Nomura T, Inoue Y, Kagimura T, Nakashima K. Clinical significance of REM sleep behavior disorder during REM sleep. Brain. (2007) 130:450–6. doi: 10.1093/brainawl363

13. Postuma RB, Molano JR, Ferman TJ, Smith GE, Lin S-C, Bieniek K, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. (2011) 12:445–5. doi: 10.1016/j.sleep.2010.12.009

14. American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual (ICSD-2). 2nd ed. Westchester, IL: American Academy of Sleep Medicine (2005).

15. Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin S-C, Bieniek K, et al. Risk of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in Parkinson’s disease. Mov Disord. (2020) 35:2649–53. doi: 10.1002/mds.34249

16. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. (1959) 32:50–5. doi: 10.1111/j.2044-8341.1959.tb0467x

17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. (1967) 30:56–62. doi: 10.1136/jnnp.31.3.56

18. Munich Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. (2005) 53:695–9. doi: 10.1111/j.1532-5415.2005.55221.x

19. Petru V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol. (1998) 245 Suppl. 1:510–14. doi: 10.1007/PL00007730

20. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. (1992) 15:376–81. doi: 10.1093/sleep/15.4.437

21. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. (2002) 17:867–76. doi: 10.1002/mds.10248

22. Doty RL, Shanan P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. (1994) 94:76–8. doi: 10.1289/00005537-19940200-00004

23. Ferezhtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain. (2017) 140:1959–76. doi: 10.1093/brain/awx118

24. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry. (2008) 79:387–91. doi: 10.1136/jnnp.2007.116830

25. Figorilli M, Marques AR, Vidal T, Delaby L, Meloni M, Pereira B, et al. Does REM sleep behavior disorder change in the progression of Parkinson’s disease? Sleep Med. (2020) 68:1980–8. doi: 10.1016/j.sleep.2019.12.013

26. Rahayel S, Gaubert M, Postuma RB, Montplaisir J, Carrier J, Monchi O, et al. Brain atrophy in Parkinson’s disease with polysomnography–confirmed predictors of progression. Mov Disord. (2018) 33:1829–37. doi: 10.1002/mds.27381
REM sleep behavior disorder. *Sleep*. (2019) 42:zsz062. doi: 10.1093/sleep/zsz062

37. Salsone M, Cerasa A, Arabia GM, Gambardella A, Mumoli L, et al. Reduced thalamic volume in Parkinson disease with REM sleep behavior disorder: volumetric study. *Parkinsonism Relat. Disord.*. (2014) 20:1004–8. doi: 10.1016/j.parkreldis.2014.06.012

**Conflict of Interest:** RD reports personal fees (consulting) from Amneal, Acorda, Supernus, Teva, Adamas, US WorldMeds, Acadia, and Lundbeck, outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Barasa, Wang and Dewey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*